2019-nCoV: how stable are coronaviruses in the environment? | MediPaper

Non-Sponsored Content

INFECTIOUS DISEASE

2019-nCoV: how stable are coronaviruses in the environment?

Analyzed by: Dr Siddharth Sridhar, Specialist in Clinical Microbiology & Infection | Last updated: 2nd February 2020 | In: COVID-19, Critical Care Medicine, Infectious Disease, Internal Medicine, Pneumonia, SARS-CoV2

Article Keywords

2019-nCoV, China, corona virus, COVID-19, pneumonia, WARS

Here, I look at how stable coronaviruses are on a variety of environmental surfaces.

The message is clear:

Coronaviruses are fairly stable and can survive for several hours to days on a variety of surfaces in the cool weather currently prevalent in HK.
In addition to mask wearing, hand hygiene is important to prevent coronavirus infection.
Degowning after caring for confirmed cases must be carefully supervised.
Environmental disinfection of healthcare settings and public areas is important. Close toilet lids before flushing!

YOU MAY ALSO LIKE

content continues below

Combination therapy with a novel agent, albuvirtide, in hospitalised AIDs patients

3rd November 2021

Combination therapy with a novel agent, albuvirtide, in hospitalised AIDS patients

Pfizer-BioNTech COVID-19 Vaccine for Ages 5 to 11 Years

3rd November 2021

BioNTech COVID-19 vaccine for ages 5 to 11 years – To jab or not to jab?

Dr Siddharth Sridhar - How stable are coronaviruses in the environment? COVID-19 2019-nCoV WuhanOutbreak Pneumonia

YOU MAY ALSO LIKE

Combination therapy with a novel agent, albuvirtide, in hospitalised AIDs patients

Combination therapy with a novel agent, albuvirtide, in hospitalised AIDS patients

Pfizer-BioNTech COVID-19 Vaccine for Ages 5 to 11 Years

BioNTech COVID-19 vaccine for ages 5 to 11 years – To jab or not to jab?

Gender-related differences in safety

Gender-related differences in safety after switching to BIC/TAF/FTC

Effect of HIV infection on growth and bone density in peripubertal children under antiretroviral therapy

Effect of HIV infection on growth and bone density in peripubertal children under antiretroviral therapy

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

© Copyright 2020 Dr Sridhar Siddharth – 2019-nCoV: how stable are coronaviruses in the environment?

YOU MAY ALSO LIKE

Combination therapy with a novel agent, albuvirtide, in hospitalised AIDs patients

Combination therapy with a novel agent, albuvirtide, in hospitalised AIDS patients

Pfizer-BioNTech COVID-19 Vaccine for Ages 5 to 11 Years

BioNTech COVID-19 vaccine for ages 5 to 11 years – To jab or not to jab?

Gender-related differences in safety

Gender-related differences in safety after switching to BIC/TAF/FTC

Effect of HIV infection on growth and bone density in peripubertal children under antiretroviral therapy

Effect of HIV infection on growth and bone density in peripubertal children under antiretroviral therapy

Safety and Immunogenicity of the BNT162b2 mRNA Covid-19 Vaccine in Patients after Allogeneic HCT or CD19-based CAR-T therapy

Safety and Immunogenicity of the BNT162b2 mRNA Covid-19 Vaccine in Patients after Allogeneic HCT or CD19-based CAR-T therapy

The Role of Patient Blood Management for Inflammatory Bowel Disease-01

The Role of Patient Blood Management for Inflammatory Bowel Disease

COVID-19 impacting regular patient care for cardiovascular diseases

COVID-19 impacting regular patient care for cardiovascular diseases

SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy

SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy

Toxic vaccine disinformation_有關疫苗的虛假信息

有關疫苗的虛假信息

Patient Blood Management and Treatment of iron Deficiency Anaemia in Gynaecological Conditions

Patient Blood Management and Treatment of iron Deficiency Anaemia in Gynaecological Conditions

Evidence-of-SARS-CoV2-in-heart-cells

Evidence of SARS-CoV2 in heart cells

triple-combination-effective-for-hospital-and-ventilator-acquired-pneumonia

Triple combination effective for hospital- and ventilator-acquired pneumonia

risk-of-thrombosis-with-sars-cov-2-infection

Risk of thrombosis with SARS-CoV-2 infection

no-difference-in-kidney-transplantation-outcomes-for-HIV-positive-recipients-regardless-of-donor-HIV-status

No difference in kidney transplantation outcomes for HIV-positive recipients regardless of donor HIV status

residual-risk-of-hepatocellular-carcinoma-in-older-hepatitis-c-patients-even-after-viral-clearance

Residual risk of hepatocellular carcinoma in older Hepatitis C patients even after viral clearance

potential-protective-effects-of-the-influenza-vaccine-on-cardiovascular-outcomes-in-high-risk-populations

Potential protective effects of the influenza vaccine on cardiovascular outcomes in high-risk populations

updated-human-papillomavirus-vaccination-and-testing-recommendations-from-the-american-cancer-society

Updated human papillomavirus vaccination and testing recommendations from the American Cancer Society

interim-results-of-a-Phase-2b-3-trial-investigating-a-long-acting-injectable-of-cabotegravir-for-pre-exposure-prophylaxis-of-HIV

Interim results of a Phase 2b/3 trial investigating a long-acting injectable of cabotegravir for pre-exposure prophylaxis of HIV

comparison-of-the-metabolic-changes-from-the-tango-trial-a-post-hoc-analysis

Comparison of the metabolic changes from the TANGO trial: a post-hoc analysis

Carboplatin plus paclitaxel to be the new standard of care for anal cancer

Carboplatin plus paclitaxel to be the new standard of care for anal cancer

Dr Sridhar Siddharth - Clinical characteristics of patients with 2019-nCoV pneumonia COVID-19 2019-nCoV WuhanOutbreak Pneumonia

Updated: Clinical characteristics of patients with COVID-19

Dr Siddharth Sridhar - 2019-nCoV COVID-19 in Hong Kong - the end of the beginning

COVID-19 in Hong Kong: the end of the beginning?

Dr Siddharth Sridhar - 2019-nCoV COVID-19 - How do People get Covid-19 in Hong Kong 在本港，人們如何感染Covid-19

How do people get COVID-19 in Hong Kong

Dr Siddharth Sridhar - 2019-nCoV - Summary of the situation in HK 2019-nCoV在本港的概況 COVID-19 2019-nCoV WuhanOutbreak Pneumonia

2019-nCoV – Summary of the situation in HK as of Feb 6, 2020

Dr Sridhar Siddharth - How infectious is novel coronavirus 2019 nCoV 新型冠狀病毒 2019-nCoV 的傳染性有多高 COVID-19 2019-nCoV WuhanOutbreak Pneumonia

How infectious is novel coronavirus (2019-nCoV)

Dr Sridhar Siddharth - Who gets severe novel coronavirus (2019-nCoV) infection COVID-19 2019-nCoV WuhanOutbreak Pneumonia

Who gets severe novel coronavirus (2019-nCoV) infection?

Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

FDA approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. More Information. July 31, 2018.

Lusutrombopag FDA approved for thrombocytopenia in adult chronic liver disease patients

1 reply

Trackbacks & Pingbacks

2019-nCoV: 冠狀病毒在環境中的穩定性 | MediPaper says:

25th August 2020 at 9:52 AM

[…] English Version […]

Log in to Reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply Cancel reply

You must be logged in to post a comment.

© Copyright 2020 Dr Sridhar Siddharth – 2019-nCoV: how stable are coronaviruses in the environment?

Therapeutic Areas

MediPaper Medical Communications Agency Hong Kong Blog